Gsk Share Discussion Threads

[spcecks] 27/9/2016 12:28

Your probaly right Minerve.

[minerve] 27/9/2016 11:58

Day traders don't fail if they know what they are doing; most don't because they haven't had professional tutoring. You need to learn about risk management before you day trade.

[minerve] 27/9/2016 11:57

There is a huge difference between short-term trades on the secondary market - stock exchange, and short-term 'investment' in the primary market - businesses.

You want some form of short-term trade on the markets because you want them to be liquid.

[spcecks] 27/9/2016 11:49

Also in for the dividend as day traders usually fail.

[losos] 27/9/2016 11:38

anhar -"Something like 100.1% of posts on this board and the rest of ADVFN and similar BBs elsewhere are people trying to make short term trading profits from shares"

Not me old boy :-) I'm in this business for dividend income and only sell when that looks to be in danger of a cut, or is actually cut, usually the latter since I am not privy to any kind of insider dealing unfortunately.

Edit:-
By the way, how do you get 100.1% of something ;-)

[anhar] 27/9/2016 09:24

...Yes, something must be done to curtail this ever increasing 'short term' attitude which as you say is basicly driven by what I can only term 'greed'...

Something like 100.1% of posts on this board and the rest of ADVFN and similar BBs elsewhere are people trying to make short term trading profits from shares, basically driven by what I can only term "greed".

Something must be done to curtail this ever increasing 'short term' attitude.

:~)

[philo124] 26/9/2016 17:20

Plenty of time to get it.

[essentialinvestor] 26/9/2016 17:14

Did not get to my add price today, hopefully an opportunity tomorrow.

Presidential debate later.

[tim 3] 26/9/2016 11:51

Minerve,Losos good posts agree with your points.

[alphorn] 26/9/2016 11:45

It is partly tied up as well with the fact that holding an investment gives little return because of the near zero interest rates versus the capital gain on a business sale or restructuring.

[losos] 26/9/2016 10:42

Minerve - "I think the issue is a general problem for all capitalism at the moment."

Yes, something must be done to curtail this ever increasing 'short term' attitude which as you say is basicly driven by what I can only term 'greed'

Hedge funds and private equity groups should not determine the long term outlook for a company. The current discussion on GSK is very typical. Break it up, make lots of dosh, sell the individual parts on, repeat the whole process with some other big company.

While all that is going on the people in the R&D departments don't know what the company status will be in 10 or 20 years so can hardly be blamed for not looking for genuine new discoveries.

[tradermichael] 25/9/2016 14:29

Also, statistics show that in Germany, women occupy only 8.7 percent of the management positions in companies with more than 500 employees. In fact, in 2012, women accounted for a mere 4 percent of management positions in 100 – 200 of Germany’s largest companies. According to a study conducted in 2012 by Mercer Deutschland GmbH, a management consulting firm, Germany just about manages to be ranked 28 out of 29 European countries in this regard.

[2hoggy] 25/9/2016 11:33

Alphorn

Unfortunately that is the problem with many companies in the uk,the city is too short termism when it comes to investing in companies,Germany has the right idea they have a much longer horizon with investing.

[alphorn] 25/9/2016 09:06

There will always be this friction. Big Pharma is, by definition, a very long term business as it researches and brings drugs to market. The short term investors are more interested in breaking up the business and making a quick buck.

[tradermichael] 25/9/2016 07:13

GlaxoSmithKline faces mounting investor anger over the promotion of the drugmaker’s consumer healthcare boss to the top job.

Some big shareholders in the FTSE 100 giant are understood to be unhappy with the decision to appoint Emma Walmsley to succeed Sir Andrew Witty as chief executive.

Her rise to the helm of the sixth-biggest company in the FTSE 100 has been hailed as a milestone in the push to increase the representation of women in boardrooms. As head of the £80bn pharmaceuticals giant, Ms Walmsley will be one of the most influential figures in British business.

However, some investors would have rather seen an external candidate appointed, and believe the promotion signals Ms Walmsley is unlikely to deviate from the strategy laid out by Sir Andrew.He had resisted investor pressure to bolster sales and profits by spinning off parts of the company.

[tradermichael] 23/9/2016 14:07

LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it has filed a U.S. regulatory submission for sirukumab in rheumatoid arthritis.

The pharmaceutical giant has submitted a biologics license application to the U.S. Food and Drug Administration by Janssen Biotech, Inc., seeking approval of a subcutaneous formulation of sirukumab for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have failed, or are intolerant to one or more disease-modifying antirheumatic drugs.

Sirukumab is being co-developed for rheumatoid arthritis as part of a collaboration with Janssen Biologics (Ireland), an affiliate of JBI.

A regulatory submission to the European Medicines Agency was announced on Sept. 12. Sirukumab is currently not approved as a treatment for any indication anywhere in the world.

[badtime] 22/9/2016 12:22

Pocket money to you EI :)

[essentialinvestor] 22/9/2016 08:18

CNBC highlighted a case of price gouging yesterday, an extraordinary situation
of an anti acne creme being sold for $ thousands, thousands for one tube of cream.

[dr biotech] 22/9/2016 07:55

Quite a good rise in the US last night, hopefully positive opening this morning

[kiwi2007] 22/9/2016 00:16

Useful comment...



N.B. Probably worth holding just as an anti-dote to the constantly falling UKPound.

[rzw2201] 21/9/2016 21:06

Emma is with GSK since 2010 and is heading GSK consumer healthcare since 2012... Before she was for 17 years with l'Oriel, cosmetics which is another regulated industry. With her modern languages degrees, she is an excellent international communicator. It's the great communicators with high emotional intelligence that make the best leaders. She is MORE than qualified or experienced to head GSK. Read up...

[essentialinvestor] 21/9/2016 20:49

Nice intra-day reversal for GSK stateside.

Added a few more before the close.

[minerve] 21/9/2016 16:04

In addition to Hilary.....